Table 3. Results for measurement of urinary AG31 in the diagnosis of non-muscle invasive bladder cancer (NMIBC) patients.

Test							Validation
AUC (95% CI)	Sensitivity	Specificity	PPV	NPV	Positive LR	Negative LR	AUC (95% CI)	Sensitivity	Specificity	PPV	NPV	Positive LR	Negative LR
NMIBC vs HC
0.9574 (0.9310- 0.9838)	0.9104	0.9153	0.9242	0.9000	10.7433	0.0978	0.9790 (0.9720-0.9860)	0.9232	0.9442	0.9617	0.8901	16.5354	0.0814
NMIBC vs HC+Cystitis+Nephritis+Prostatitis
0.9524 (0.9248- 0.9800)	0.9104	0.9135	0.8841	0.9337	10.5271	0.0980	0.9758 (0.9684-0.9833)	0.9232	0.9325	0.9312	0.9246	13.6862	0.0824

HC, healthy control; NMIBC, non-muscle invasive bladder cancer; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio; CI, confidence interval.